🎙️ "We’ve come a long way. Patients in Romania now can access the same treatments as Western Europe."
– Dr. Maria Barbu at #IUCS2024
From ADT to abiraterone and olaparib, hear how prostate cancer care is evolving in Eastern Europe.
📺 Watch now: youtu.be/H5mCmUzb_N4
🌐 Learn more at: oncoassist.com
🚨 New #OncologyBytes Episode!
Prof. Nikhil Vasdev explains the groundbreaking TAR-200 therapy in the SunRISe-5 trial, offering sustained gemcitabine release for high-risk recurrent #NMIBC post-BCG.
📺 Watch now: youtu.be/rFvsGjVIOQM
🌐 Learn more at: oncoassist.com
#IUCS2024 #BladderCancer
New on #OncologyBytes from #IUCS2024
Dr. Francis Sundram shares Southampton’s 3-year experience with #PSMATherapy in mCRPC patients.
📊 10 patients, 50+ cycles, minimal toxicity, strong relief.
📺 Watch: youtu.be/pzdtlG0yq7w
🌐 Learn more at: oncoassist.com
#Lutetium177 #mCRPC #ProstateCancer
🎥 New on #OncologyBytes from #IUCS2024
Dr. Mona Hassan on low-volume mHSPC:
📊 PSA may be a key prognostic factor.
📉 Treatment patterns remain inconsistent.
📺 Watch: youtu.be/UNbeQ2Gv8iE
🌐 Learn more at: oncoassist.com
#mHSPC #ProstateCancer #RealWorldData #Oncoassist #oncoalert
🎥 New on #OncologyBytes from #IUCS2024
Dr. Aruni Ghose presents results from validating the MEET-URO score across 1,100+ mRCC patients.
📊 Higher accuracy than IMDC. Cited in EAU guidelines.
📺 Watch: youtu.be/jC1d4H8WmOk
🌐 Learn more at: oncoassist.com
#mRCC #RenalCancer #MEETURO #Oncoassist
🎥 New on #OncologyBytes from #IUCS2024
Dr. Sara Rebuzzi breaks down MEET-URO 33 study results:
📊 How baseline factors guide first-line mRCC treatment decisions.
📺 Watch: youtu.be/wY9oM5PzJ1o
🌐 Learn more at: oncoassist.com
#mRCC #RenalCancer #RealWorldData #FirstLineTherapy #Oncoassist #oncoalert
🎥 New on #OncologyBytes from #IUCS2024
Dr. Anupama Vijay shares a real-world UK audit of 1L mRCC treatment.
📊 Only 64% of patients received 2L therapy after progression.
📺 Watch: youtu.be/Qix6-H83_nw
🌐 Learn more at: oncoassist.com
#mRCC #RenalCancer #CheckpointInhibitors #Oncoassist #UKOncology
🎥 New on #OncologyBytes from #IUCS2024
Dr. Yüksel Ürün validates the MEET-URO prognostic score in real-world mRCC patients treated with Ipi/Nivo, Cabo/Ipi/Nivo & Pembro/Axi.
📺 Watch: youtu.be/k2BA8sVHD-Y
🌐 Learn more at: oncoassist.com
#mRCC #RenalCancer #PrognosticScore #CheckpointInhibitors
🎥 New on #OncologyBytes from #IUCS2024
Dr. Fabrizio Di Costanzo: Can TK1 track treatment response in mHSPC?
📉 Early data shows TK1 & PSA decline together in most patients.
📺 Watch: youtu.be/3w44UNUP890
🌐 Learn more at: oncoassist.com
#ProstateCancer #Biomarkers #mHSPC #TK1 #Oncoassist #CancerCare
🎥 New on #OncologyBytes from #IUCS2024
Dr. Vishwani Chauhan introduces a real-world prognostic score for metastatic bladder cancer patients on immunotherapy.
📊 Risk-based survival from 2–17 months.
📺 Watch:https://youtu.be/FfDd24yOI-0
🌐 Learn more at: oncoassist.com
#BladderCancer #mBladderCancer
🎥 New on #OncologyBytes from #IUCS2024
Dr Michele Maffezzoli validates the GRANT Score in papillary RCC - 1,900+ patients, real-world data.
📊 Accurate, simple, risk-stratified survival prediction.
📺 Watch: youtu.be/38shXSOsUNI
🌐 Learn more at: oncoassist.com
#PapillaryRCC #GRANTScore #Oncoassist
🎥 New on #OncologyBytes from #IUCS2024
Dr. Davide Bimbatti breaks down real-world trends in first-line immunotherapy choices for mRCC.
👨⚕️ 500+ pts | IO+TKI vs IO+IO | Risk-based decisions
📺 Watch: youtu.be/49jr9Cp64Wo
🌐 Learn more: oncoassist.com
#KidneyCancer #mRCC #Immunotherapy #Oncoalert
🎥 New on #OncologyBytes (IUCS 2024)
A rare prostate cancer case: Brain mets despite undetectable PSA.
Dr. Luciano Stumbo breaks it down — and why MRI matters.
📺 Watch: youtu.be/nFg2XbgkzrQ
🌐 More at: oncoassist.com
#IUCS2024 #ProstateCancer #BrainMetastases #Oncoassist #CancerCare #Oncoalert
